Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100.

  • Åsa Ström
  • Gunilla Nordin Fredrikson
  • Alexandru Schiopu
  • Irena Ljungcrantz
  • Ingrid Söderberg
  • Bo Jansson
  • Roland Carlsson
  • Anna Hultgårdh
  • Jan Nilsson
Publishing year: 2007
Language: English
Pages: 298-305
Publication/Series: Atherosclerosis
Volume: 190
Issue: 2
Document type: Journal article
Publisher: Elsevier

Abstract english

Objective: The immune system plays an important regulatory role in the development of atherosclerotic plaques and neointima formation following various types of angioplasty. In the present study we investigated the effect of antibodies against aldehyde-modified apolipoprotein B-100 (apoB-100), a component of oxidized LDL, on atherosclerosis and response to arterial injury in mice. Methods: The ability of a high affinity human recombinant antibody (21303), specific for malondialdehyde-modified apoB-100, to influence formation of atherosclerosis as well as remodelling and neointima formation after a collar-induced injury of the carotid artery was studied in LDL receptor(-/-) mice over-expressing human apoB-100. Results: The antibody recognized epitopes present in mouse plasma and reduced the plasma level of oxidized LDL by 34%. Antibody treatment inhibited injury-induced restrictive vascular remodelling but did not influence the size of the neointima. Atherosclerosis in the uninjured contra lateral carotid artery was determined by computerized image analysis and the mean plaque area in animals given control IgG1 was 7608 +/- 10,336 mu m(2). In contrast, essentially no plaques were present in animals treated with the 2DO3 antibody (397 +/- 235 mu m(2), P < 0.0 1 versus control IgG 1). Conclusions: Treatment with antibodies against aldehyde-modified apoB-100 dramatically reduces atherosclerosis and inhibits restrictive vascular remodelling in mice expressing human apoB-100. (c) 2006 Elsevier Ireland Ltd. All rights reserved.


  • Cardiac and Cardiovascular Systems
  • atherosclerosis
  • oxidized LDL
  • apolipoprotein B-100
  • antibodies
  • vascular injury


  • Vessel Wall Biology
  • Cardiovascular Research - Immunity and Athersosclerosis
  • ISSN: 1879-1484
E-mail: jan [dot] nilsson [at] med [dot] lu [dot] se

Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00